<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04908345</url>
  </required_header>
  <id_info>
    <org_study_id>MEFERENAL</org_study_id>
    <nct_id>NCT04908345</nct_id>
  </id_info>
  <brief_title>Methadone Anesthesia For Kidney Transplant Receptors</brief_title>
  <official_title>Intraoperative Use Of Methadone In The Prevention of Postoperative Pain in Kidney Transplant Receptors</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Sao Paulo General Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University of Sao Paulo General Hospital</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Intraoperative methadone or fentanyl will be administered to patients submitted to kidney&#xD;
      transplant surgery. Postoperative pain, analgesic consumption and side effects will be&#xD;
      evaluated&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Despite recent developments in postoperative pain control, many patients still experience&#xD;
      moderate or severe pain after surgery. It is estimated that severe postoperative pain occurs&#xD;
      in 20 to 40% of surgical procedures. With the development of kidney transplant services, a&#xD;
      better study of the intraoperative analgesia used in this procedure and its impact on the&#xD;
      postoperative is necessary. The management of postoperative pain in renal transplant&#xD;
      recipients is essential to improve the quality of postoperative care, and may even impact the&#xD;
      prognosis of the renal graft. One of the strategies to improve pain control in the&#xD;
      perioperative period is the intraoperative use of intravenous methadone, given its&#xD;
      pharmacokinetic profile. Methadone is an opioid agonist of µ receptors, it is also a&#xD;
      Glutamate antagonist by blocking the N-methyl-D-aspartate (NMDA) receptor, and inhibits the&#xD;
      reuptake of serotonin and norepinephrine. When administered in doses of 20 to 30mg, the&#xD;
      analgesia generated by methadone can last from 24 to 36 hours. There is also evidence that&#xD;
      the use of methadone in doses of 0.2 to 0.3 mg / kg is not associated with a higher incidence&#xD;
      of side effects when compared to other opioids with short or intermediate duration of action,&#xD;
      such as fentanyl, sufentanil and morphine. The aim of this study is to evaluate the&#xD;
      effectiveness of using intraoperative methadone to reduce postoperative pain in patients&#xD;
      undergoing kidney transplant surgery (recipients). Patients will be submitted to standardized&#xD;
      general anesthesia, and the opioid used in anesthetic induction will be methadone or fentanyl&#xD;
      with additional boluses if necessary. After extubation, Fentanyl will be installed in an&#xD;
      intravenous analgesia pump controlled by the patient. Differences between groups regarding&#xD;
      opioid consumption, pain scores, side effects and patient satisfaction will be assessed&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">May 17, 2021</start_date>
  <completion_date type="Anticipated">January 2022</completion_date>
  <primary_completion_date type="Anticipated">January 2022</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>Methadone x Fentanyl</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Pain score 24h postoperatively</measure>
    <time_frame>One day after surgery</time_frame>
    <description>Reported pain in a scale of 0 (no pain) to 10 (maximum pain)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Pain score 48h postoperatively</measure>
    <time_frame>Two days after surgery</time_frame>
    <description>Reported pain in a scale of 0 (no pain) to 10 (maximum pain)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Pain score 72h postoperatively</measure>
    <time_frame>Three days after surgery</time_frame>
    <description>Reported pain in a scale of 0 (no pain) to 10 (maximum pain)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Analgesic use 24h postoperatively</measure>
    <time_frame>One day after surgery</time_frame>
    <description>Analgesic use after surgery</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Analgesic use 48h postoperatively</measure>
    <time_frame>Two days after surgery</time_frame>
    <description>Analgesic use after surgery</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Analgesic use 72h postoperatively</measure>
    <time_frame>Three days after surgery</time_frame>
    <description>Analgesic use after surgery</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Opioid-related side effects 24h postoperatively</measure>
    <time_frame>One day after surgery</time_frame>
    <description>Opioid-related side effects</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Opioid-related side effects 48h postoperatively</measure>
    <time_frame>Two days after surgery</time_frame>
    <description>Opioid-related side effects</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Opioid-related side effects 72h postoperatively</measure>
    <time_frame>Three days after surgery</time_frame>
    <description>Opioid-related side effects</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">32</enrollment>
  <condition>Renal Failure Chronic</condition>
  <condition>Surgery</condition>
  <arm_group>
    <arm_group_label>Methadone</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Methadone 0,075mg/kg for induction and half of induction dose of boluses as needed during surgery</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Fentanyl</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Fentanyl 3 mcg/kg for induction and half of induction dose of boluses as needed during surgery</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Methadone</intervention_name>
    <description>Used at induction and during surgery</description>
    <arm_group_label>Methadone</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Fentanyl</intervention_name>
    <description>Used at induction and during surgery</description>
    <arm_group_label>Fentanyl</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Patients over 18 years of age&#xD;
&#xD;
          -  With indication for kidney transplant surgery&#xD;
&#xD;
          -  Who sign the informed consent form&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Patients who refuse to participate in the study&#xD;
&#xD;
          -  Known allergy to any drug used in this protocol&#xD;
&#xD;
          -  Presence of stage III or IV congestive heart failure&#xD;
&#xD;
          -  Increase in QT interval on electrocardiogram (QT&gt; 500 msec)&#xD;
&#xD;
          -  Preemptive kidney transplantation (defined by transplantation in a patient who has not&#xD;
             yet started kidney replacement therapy).&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Felipe C Machado, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>USP</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Felipe C Machado, MD, PhD</last_name>
    <phone>+551126616335</phone>
    <phone_ext>6335</phone_ext>
    <email>felipe.chiodini@hc.fm.usp.br</email>
  </overall_contact>
  <location>
    <facility>
      <name>Hospital das Clínicas da FMUSP</name>
      <address>
        <city>Sao Paulo</city>
        <state>SP</state>
        <zip>05403-000</zip>
        <country>Brazil</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Felipe Machado, MD</last_name>
      <phone>+551126617947</phone>
      <email>felipe.chiodini@hotmail.com</email>
    </contact>
  </location>
  <location_countries>
    <country>Brazil</country>
  </location_countries>
  <verification_date>May 2021</verification_date>
  <study_first_submitted>May 20, 2021</study_first_submitted>
  <study_first_submitted_qc>May 25, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">June 1, 2021</study_first_posted>
  <last_update_submitted>May 25, 2021</last_update_submitted>
  <last_update_submitted_qc>May 25, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">June 1, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of Sao Paulo General Hospital</investigator_affiliation>
    <investigator_full_name>Felipe Chiodini Machado</investigator_full_name>
    <investigator_title>Principal Investigator</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Kidney Failure, Chronic</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Fentanyl</mesh_term>
    <mesh_term>Methadone</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

